These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9109740)

  • 61. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
    Trouillas P; Garde A; Robert JM; Renaud B; Adeleine P; Bard J; Brudon F
    Rev Neurol (Paris); 1982; 138(5):415-35. PubMed ID: 6983101
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study.
    Trouillas P; Serratrice G; Laplane D; Rascol A; Augustin P; Barroche G; Clanet M; Degos CF; Desnuelle C; Dumas R
    Arch Neurol; 1995 May; 52(5):456-60. PubMed ID: 7733839
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients.
    Levin HS; Peters BH; Kalisky Z; High WM; von Laufen A; Eisenberg HM; Morrison DP; Gary HE
    Cent Nerv Syst Trauma; 1986; 3(4):333-42. PubMed ID: 3555852
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cholinergic influences in tardive dyskinesia.
    Tamminga CA; Smith RC; Ericksen SE; Chang S; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):769-74. PubMed ID: 869054
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease.
    Schulte T; Mattern R; Berger K; Szymanski S; Klotz P; Kraus PH; Przuntek H; Schöls L
    Arch Neurol; 2001 Sep; 58(9):1451-7. PubMed ID: 11559318
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Physostigmine improves ECT-induced memory disturbances.
    Levin Y; Elizur A; Korczyn AD
    Neurology; 1987 May; 37(5):871-5. PubMed ID: 3574695
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
    Trouillas P; Garde A; Robert JM; Adeleine P
    C R Seances Acad Sci III; 1981 Jan; 292(1):119-22. PubMed ID: 6786764
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.
    Kertzman C; Robinson DL; Litvan I
    Arch Neurol; 1990 Dec; 47(12):1346-50. PubMed ID: 2252453
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia.
    Benussi A; Dell'Era V; Cotelli MS; Turla M; Casali C; Padovani A; Borroni B
    Brain Stimul; 2017; 10(2):242-250. PubMed ID: 27838276
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The acute cerebellar ataxia, reccurrence of disease after 5 years--a case report].
    Sobolewski P
    Przegl Epidemiol; 2006; 60 Suppl 1():148-50. PubMed ID: 16909793
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Choline chloride in the treatment of ataxia.
    Livingstone IR; Mastaglia FL
    Br Med J; 1979 Oct; 2(6195):939. PubMed ID: 391326
    [No Abstract]   [Full Text] [Related]  

  • 76. Treatment of cerebellar ataxia with 5-HT1A agonist.
    Takei A; Hamada T; Yabe I; Sasaki H
    Cerebellum; 2005; 4(3):211-5. PubMed ID: 16147954
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dose-related physostigmine-induced ventricular arrhythmia: case report.
    Dysken MW; Janowsky DS
    J Clin Psychiatry; 1985 Oct; 46(10):446-7. PubMed ID: 4044537
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interaction of physostigmine and alfentanil in a human pain model.
    Wehrfritz AP; Ihmsen H; Schmidt S; Müller C; Filitz J; Schüttler J; Koppert W
    Br J Anaesth; 2010 Mar; 104(3):359-68. PubMed ID: 20047897
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Buspirone chlorhydrate in the treatment of cerebellar ataxia].
    Andrade-Filho AS; Passos-Almeida J; Andrade-Souza VM; Sena-Pereira LR
    Rev Neurol; 2002 Aug 16-31; 35(4):301-5. PubMed ID: 12235556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.